




































Art of Medicine           Volume-1 

International Medical Scientific Journal        Issue-3 

10.5281/zenodo.5658996 

49 

  



Art of Medicine           Volume-1 

International Medical Scientific Journal        Issue-3 

10.5281/zenodo.5658996 

50 

 

Art of Medicine International Medical Scientific journal 

 

Founder and Publisher Pascual Izquierdo-Egea 

Published science may 2021 year. Issued Quarterly. 

Internet address: http://artofmedicineimsj.us 

E-mail: info@artofmedicineimsj.us 

11931 Barlow Pl Philadelphia, PA 19116, USA +1 (929) 266-0862 

 

 
   

  



Art of Medicine           Volume-1 

International Medical Scientific Journal        Issue-3 

10.5281/zenodo.5658996 

51 

 

Difficulties and prospects for non-drug treatment of metabolic syndrome 

Badritdinova Matluba Nazhmidinovna., Nurulloeva Shakhodat Nurullo kizi 

Bukhara State Medical Institute, Bukhara, Uzbekistan 

 

Abstract: Abdominal obesity (and the closely related metabolic syndrome) is 

one of the most common diseases in the world. The urgency of the problem of the 

progression of abdominal obesity lies not only in its widespread prevalence, but also 

in the formation of a high risk of developing cardiovascular diseases and type 2 

diabetes mellitus. The main reasons for the rapid development of obesity are 

considered high-calorie nutrition (which includes not only the quantity, but also the 

quality of food eaten), a sedentary lifestyle and a genetic predisposition. Until now, 

there has been a heated debate about methods for fast and high-quality weight loss. 

There are many studies on the treatment of the various components of 

metabolic syndrome. Despite the many different pharmaceuticals developed for the 

treatment of abdominal obesity, non-drug methods of treatment and the organization 

of a healthy lifestyle come out on top, which is a difficult and, at times, 

overwhelming task for the clinician. 

One of the main reasons for failure in this field is the lack of time at the doctor 

for outpatient appointments. To address this issue, the role of the "Schools of Health" 

is considered in order to effectively reduce the body weight of patients with 

metabolic syndrome and maintain long-term results. A review of the prevalence and 

main causes of abdominal obesity is carried out, the results of existing schools in real 

clinical practice for the treatment of various chronic diseases are analyzed, an 

assessment of their effectiveness is given. 

Keywords: metabolic syndrome, obesity, diet. 

 

Introduction: Metabolic syndrome (MS) is characterized by an increase in 

visceral fat mass, decreased sensitivity of peripheral tissues to insulin, and 

hyperinsulinemia, which cause the development of disorders of carbohydrate, lipid, 

purine metabolism and arterial hypertension (AH). The problem of MS progression is 

one of the most pressing problems of modern medicine, associated not only with 

leading an unhealthy lifestyle, excessive nutrition and physical inactivity, but also 

with a genetic predisposition [1]. 

Metabolic syndrome is gaining importance in the world. The number of 

patients increases dramatically every year. More than 1 billion people on our planet 

are overweight and over 300 million are obese. According to the WHO, the number 

of patients with a high risk of developing diabetes mellitus (including insulin 

resistance and obesity) is 40-50 million people in Europe [2]. According to various 

authors, in industrialized countries among the population over 30, the prevalence of 

MS ranges from 10 to 20% [3,4]. 

The prevalence of MS in Western countries, according to various sources, is 

25-35% of the population, increasing with age. At the age of 60 and older, MS 

accounts for 42-43.5%. More than 47 million people in the United States have MS [5-



Art of Medicine           Volume-1 

International Medical Scientific Journal        Issue-3 

10.5281/zenodo.5658996 

52 

7]. In developing countries, including Russia and Belarus, about 30% of the 

population is overweight [8.9]. There is a high increase in the incidence of MS 

among adolescents [10-14]. The prevalence of MS among men and women is equal: 

in men - 24%, among women - 23.4%, with than in women, the incidence of MS 

increases in the postmenopausal period [14,15]. 

Тarget. To study the role of non-drug methods of treatment of metabolic 

syndrome based on the results of clinical studies. 

Results and Discussions. 

The clinical significance of disorders and diseases united by the framework of 

the syndrome is that their combination greatly accelerates the development and 

progression of diseases associated with atherosclerosis. The latter, according to WHO 

estimates, rank first among the causes of mortality in the population of industrially 

developed countries [23-25]. 

Thus, in addition to the epidemiological aspect, MS is a serious factor of 

cardiovascular risk and the risk of developing type 2 diabetes, affects life expectancy 

and its quality. In recent years, more and more information has been accumulating on 

the relationship of metabolic disorders with cardiovascular morbidity (CVD) and 

mortality [13, 26-28,35]. 

It has been proven that it is patients with MS who are at risk of rapid 

development of diabetes mellitus and various forms of coronary artery disease [25, 

27, 29]. 

In the 21st century, for mankind, which has overcome the epidemic of life-

threatening infections over a centuries-old history, the problem of CVD has come to 

the fore in relevance among all causes of morbidity and mortality. 

A significant role in this was played by lifestyle modification associated with 

limiting physical activity, increasing the calorie content of food, and a steady increase 

in emotional stress. All this potentiates the main risk factors for CVD, namely, an 

increase in blood pressure (BP), dyslipidemia, diabetes mellitus and obesity [6, 30, 

31]. 

Obesity is recognized as one of the most significant risk factors for the 

development of CVD, early disability of patients and premature mortality [25, 32]. 

According to the Framingham Heart Study, obesity was found to be an 

independent risk factor for all-cause mortality [33]. With obesity of 1 degree, the risk 

of developing diabetes increases by 2-3 times, 2 degrees - 5 times, and 3 degrees - 10 

times [34]. To date, it has been proven that the most dangerous in relation to the 

development of various diseases is the visceral type of obesity [25], which is 

widespread in modern society and is the main and mandatory criterion for MS [8,21, 

28-34]. 

Тhe problem of MS development is directly related to lifestyle and poor 

nutrition. Over the years, hundreds and even thousands of works devoted to MC have 

accumulated [20]. Pharmaceutical companies have invented a huge number of drugs 

that affect various links in the pathogenesis of MS. But, despite the successes, in this 

direction there are no positive shifts in solving this problem as a whole. 



Art of Medicine           Volume-1 

International Medical Scientific Journal        Issue-3 

10.5281/zenodo.5658996 

53 

Throughout humanity, anthropometric data have constantly changed, mainly 

due to an increase in height, to a lesser extent - due to an increase in body weight.    

Things have changed dramatically lately. The lifestyle of a modern person has 

changed dramatically and ceased to correspond to the concept of healthy. Instead of 

national cuisines, a high-calorie diet has come: universal "McDonaldization", "Coca-

Colanization" of the population. 

In large industrial cities, most of the working-age population among the choice 

of places for public catering prefers various fast food cafes, where they often offer 

food containing large the amount of fats, carbohydrates, salt, sugar, low in fiber, 

vitamins and minerals. 

Therefore, lifestyle modification and diet therapy remain the primary treatment 

strategies for MS. MS before the development of type 2 diabetes mellitus is a 

reversible condition, thus, by making a diagnosis and starting treatment, regression of 

the main manifestations can be achieved. The main goal of MS treatment is to reduce 

the risk of developing CVD and type 2 diabetes. Therapeutic measures in the 

treatment of patients with MS should correct the main links of its pathogenesis [17]. 

The main tasks in the treatment of patients with MS are: weight loss, achieving 

good metabolic control, achieving an optimal blood pressure level, preventing acute 

and long-term cardiovascular complications (CVC). 

The main component of MS, triggering a further pathological mechanism of 

metabolic disorders, is abdominal obesity (AO).  

Treatment of AO is acquiring important medical importance, since the increase 

in waist volume is directly associated with a number of disorders that affect life 

expectancy, ahead of such serious risk factors as smoking and alcohol abuse [28]. It 

is the normalization of body weight that causes a decrease in insulin resistance, an 

improvement in insulin sensitivity, a decrease in blood pressure and regression of 

impaired functions. 

According to the WHO, the health of the population is 70% conditioned by the 

lifestyle, therefore an important factor in the fight against CVD is the formation of a 

healthy lifestyle [19, 29, 30]. 

Data from three large studies (Da Qing stady, DPP, FDP) have shown that 

lifestyle changes in people with MS reduce the risk of developing diabetes by more 

than 50% [31,34]. It has been proven that diet and moderate exercise for at least 3-6 

months leads to a significant decrease in body weight by 11%, waist circumference 

by 9%, high-density lipoprotein cholesterol (LDL) levels - by 13%, triglycerides - by 

24%, improvement of insulin sensitivity - by 15% [12-14]. 

A decrease in body weight by 5.6 kg by 58% reduces the risk of further 

progression of carbohydrate metabolism, and a decrease in body weight by 10% leads 

to a decrease in overall mortality by 10%, a decrease in mortality from diabetes by 

10%, a decrease in systolic and diastolic blood pressure by 10 mm Hg, an increase in 

high-density lipoprotein (HDL) by 8%, a decrease in triglycerides (TG) by 30% [22]. 

For every 1 kg of weight loss, there is a decrease in total cholesterol by 0.05 mmol / 

L, LDL - by 0.02 mmol / L, TG - by 0.015 mmol / L, increase in HDL - by 0.009 

mmol / L [32]. 



Art of Medicine           Volume-1 

International Medical Scientific Journal        Issue-3 

10.5281/zenodo.5658996 

54 

Diet therapy is the cornerstone of the management of MS patients, and perhaps 

the most difficult to manage. Many nutritionists testify that changing their dietary 

habits for patients with MS is a difficult and sometimes daunting task [19]. Despite 

the fact that dietetics has made great strides in studying the dietary aspects of obesity 

treatment, patient adherence to changes in eating behavior remains extremely low 

[22, 28, 30]. 

Difficulties also arise for doctors who recommend weight loss to patients with 

MS. There are no clearly prescribed dietary recommendations for the treatment of 

patients with MS. There are developed dietary tables according to Pevzner, general 

recommendations for hypocaloric nutrition, food pyramids, etc. However, MS is a 

multicomponent disease, and if a Pevzner dietary table is prescribed, then all 

components should be taken into account. In case of obesity, dietary table No. 8 

according to Pevzner is prescribed, with impaired carbohydrate metabolism and type 

2 diabetes - dietary table No. 9 with restriction of carbohydrates, with hypertension 

and concomitant coronary artery disease - dietary table No. 10, with dyslipidemia - 

restriction of animal fats, with hyperuricemia and gout - limiting the intake of 

purines, etc.). In this situation, the doctor is faced with the question: what exactly 

should be prescribed in dietary recommendations. Most authors believe that the 

nutrition of patients with MS should be frequent and fractional (up to 5-6 times a day) 

in small portions, low in calories and low in fat and simple sugars. 

The optimal daily food ration includes: proteins - 15%, complex carbohydrates 

- 55%, simple carbohydrates levoda - less than 10%, fats - 30% (of which saturated 

animal fats should be less than 7%) of the daily diet [32]. Given the frequent presence 

of hypertension in patients with MS, the consumption of sodium chloride is limited to 

no more than 2-5 g / day. An increase in fiber-containing foods has been 

recommended [31]. 

It is necessary to teach patients how to calculate the daily caloric intake; to 

create a negative energy balance, the daily caloric intake should be reduced by 500 

kcal. Caloric content for each patient is is read individually using special formulas, 

taking into account such components as gender, age, physical activity [16,19]. 

On the modern pharmaceutical market there is a huge number of drugs that are 

used in the treatment of individual links in the pathogenesis of MS: antihypertensive, 

hypoglycemic, hypocholesteric, antipurine [22], but non-drug methods of treatment 

are returning to the first place in the treatment of MS [17, 21]. 

Increasing physical activity is the second most important non-drug weight loss 

method along with diet therapy. However, physical activity should be dosed and 

individual for each patient. Other methods of non-drug effects on body weight have 

been described, such as herbal medicine, the use of dietary supplements, 

psychological effects, hypnosis, and auto-training [29]. 

There is no sufficient evidence base for their widespread use; their use is 

possible only as additional methods to the main treatment. 

It should be said that the majority of patients have no concept of a healthy 

lifestyle.  Everyone knows that you shouldn't take too much alcohol, smoking is 

harmful, but the concept of healthy eating is blurred even among educated people. 



Art of Medicine           Volume-1 

International Medical Scientific Journal        Issue-3 

10.5281/zenodo.5658996 

55 

The concept of a healthy food is biased towards foods with a low glycemic 

index, which is not always correct: people 

strive to choose a product free of genetically modified and transgenic products, which 

may be correct, but by no means the primary one in the choice of products.   

On the other hand, there is no information in the media, special literature for 

patients. It is clear that if a person has the opportunity to have access to information 

on healthy eating, then his eating behavior is close to the correct one. 

Due to proper nutrition, body weight decreases, waist volume decreases, 

anthropometric indicators improve, and the risk of CVD and diabetes mellitus 

decreases [20]. 

An important task is not only to reduce weight to optimal indicators, but also to 

further maintain it at a certain level. Often, patients have no idea what their weight 

and waist circumference should be. The key point for people motivated to reduce 

their excess weight is the course approach. Changing the diet plan, lifestyle should be 

perceived by the patient relatively easily, not become burdensome, it is easy enough 

to be carried out for a long time. 

The more the doctor interferes with the patient's lifestyle and lifestyle, the less 

hope for success: competence and long-term fulfillment of any prescription is directly 

dependent on a person's motivation, personality traits, and also on the degree of 

lifestyle change. The number of recommendations that a doctor must give should be 

limited, his task is to develop a strictly limited, but most effective number of 

recommendations. 

The diet of a patient with MS should not only ensure weight loss, but also not 

cause metabolic disorders and not provoke an increase in blood pressure. 

Weight loss should be gradual. A rapid and sharp decrease in body weight by 

10–20 kg leads to a decrease in the hormone leptin, which leads to a compensatory, 

difficult to overcome feeling of hunger and an increase in food consumption [18]. 

One of the problems of withdrawal from priority tasks is the independent 

expansion of physical activity with insufficient change in the diet. 

For the treatment and prevention of many diseases (arterial hypertension, 

diabetes, bronchial asthma, etc.), Health Centers have been established in   

Uzbekistan, where "Health Schools" are successfully carried out, each of which has 

developed programs to educate patients, and which have proven their effectiveness in 

real clinical practice [5, 28, 29, 32]. Created obfor patients with alcoholism, drug 

addiction, but for patients with MS, overweight, there are no such schools. 

For the effective treatment of arterial hypertension, the “School of Health for 

Patients with Arterial Hypertension in Primary Health Care” has been successfully 

used. On the basis of many treatment-and-prophylactic institutions, "Health Centers" 

have been created, in which lectures are given on the formation of a healthy lifestyle 

for patients with arterial hypertension, bronchial asthma, diseases of the 

musculoskeletal system [22.35] 

The effectiveness of programs to reduce mortality from CVD is mainly due to 

prevention and largely depends on the active participation of patients themselves and 

their immediate family [29]. 



Art of Medicine           Volume-1 

International Medical Scientific Journal        Issue-3 

10.5281/zenodo.5658996 

56 

According to the literature, there are practically no works devoted to the 

feasibility of creating "Health Schools for Patients with MS" based on teaching 

proper nutrition, changing lifestyle, eating behavior, and correct calculation of 

physical activity. 

The introduction of an innovative program in a primary care setting makes it 

possible to improve the early detection and systematization of metabolic syndrome 

and its main components. This, in turn, enhances the early detection of various 

metabolic syndrome-related diseases. 

Measures for non-drug prevention and treatment of metabolic syndrome 

expand the range of opportunities for lifestyle modification by involving family 

members in the treatment and prophylactic process. 

The practical use of an innovative prevention program creates a 

methodological basis for the development of individual preventive strategies for 

patients with metabolic syndrome and its main components. From innovative 

technologies in the prevention of metabolic syndrome, you can use a digital program 

for calculating cardiovascular risk, which takes into account the main components of 

metabolic syndrome; the program can run on a computer, tablet and smartphone; the 

program allows the patient to self-monitor the state of the MS components and the 

level of risk [20]. 

Conclusion. Thus, among the unorganized population, there is a high 

prevalence of the main components of the metabolic syndrome, which are the main 

risk factors for CVD. The prevention technologies that exist today do not meet 

modern requirements and cannot fully get the result from their use. 

Modern prevention of metabolic syndrome and CVD requires the use of new 

innovative methods. The positive effect of preventive intervention increases 

significantly when, along with personal contact, modern information and 

communication technologies through the phone, instant messengers. 

The use of modern gadgets, diagnostic and preventive digital programs significantly 

increases the effectiveness of preventive measures. 

  



Art of Medicine           Volume-1 

International Medical Scientific Journal        Issue-3 

10.5281/zenodo.5658996 

57 

 

References: 

 

1.Aneja A., El-Atat F., McFarlane S.L. et. al. Hypertension and obesity. Recent 

Prog Horm. Res. 2004;59:169-205. 

2.Aliyeva N.A. Features endocrine status of adolescent girls with obesity of 

various origins. Vestnik Volgogradskogo Gosudarstvennogo Meditsinskogo Uni-

versiteta. 2007;(1):26-9.  

3.Adasheva T.V., Demicheva O.J. Metabolic syndrome - the basis of 

pathogenetic therapy. Lechashchiy Vrach. 2003; 10: 24-8.  

4.Berezina A.V., Belyayeva O.D., Berkovich O.A., et al. Quality of life in 

patients with abdominal obesity in reducing body weight through diet and physical 

exercise. Profilakticheskaya i Klinicheskaya Meditsina. 2011;39(2):23-30.  

5.Belostotskii A.V., Vinokurov V.G., Allenov A.M. Organization of interaction 

of health centers and offices in Moscow prevention. Byulleten 'Natsional'nogo 

Nauchno-issledovatel'skogo Instituta Obshchestvennogo Zdorov'ya Imeni N.A. 

Semashko. 2014;(1):43-6.  

6.Bubnova M.G. Obesity: Causes and mechanisms of increase in body weight, 

approaches to correction. Consilium Medicum. 2005;(5):11-9.  

7.Dedov I.I. Academician Dedov interview. Sakharnyy Diabet. 2011;1:12-4. 

8.Drapkina O.M., Korneeva O.N., Chernova E.M., Popova I.R. Obesity and non-

alcoholic fatty liver disease. Rossiyskie Meditsinskie Vesti. 2012;17(3):19-24. 

9.Drapkina O.M., Korneeva O.N., Chernova E.M. Epicardial fat and non-

alcoholic fatty liver disease. Serdtse. 2012; 11 (4): 13-5.  

10.Empana J-P., Duciemetiere P., Balkau B., Jouve X. Contribution of the 

metabolic syndrome to sudden death risk in asymptomatic men: the Paris Prospective 

Study I. Eur Heart J. 2007;9:1149-54. 

11.Fontana L., Eagon J.C., Trujillo M.E., et al. Visceral fat adipokine secretion is 

associated with systemic inflammation in obese humans. Diabetes. 2007;56(4):1010-

3. 

12.Ford E.S., Giles W.H., Mokdad A.H. et al. Increasing prevalence of the 

metabolic syndrome among u.s. Adults. Diabetes Care. 2004;27(10):2444-9. 

13.Gheita T.A., El-Fishawy H.S., Nasrallah M.M., Hussein H. Insulin resistance 

and metabolic syndrome in primary gout. Int J Rheum Dis. 2012;15(6):521-5. 

14.Hajer G.R., van Haeften T.W., Visseren F.L. Adipose tissue dysfunction in 

obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29(24):2959-71. 

15.Hamdi O., Porramaticul S., A-Ozairi E. Metabolic obesity: the paradox 

between visceral and subcutaneous fat. Curr. Diabetes Rev. 2006;2(4):367-73. 

16.Juraeva Kh.I. Frequency of meeting the main components of the metabolic 

syndrome during disturbance of different phases of glycemic 

curve/Badridinova B.K., Kadirov B.S., Majidova M.A., Yakhyaeva Kh. 

Sh., Negmatullaeva M.A., Amonov M.K//ACADEMICIA:An International Multi-

disciplinary Research Journal. 2019 No. 1. - P. 80 - 85. 



Art of Medicine           Volume-1 

International Medical Scientific Journal        Issue-3 

10.5281/zenodo.5658996 

58 

17.Ivashkin V.T., Drapkina O.M., Korneeva O.N. Clinical variants of metabolic 

syndrome. Moscow: Medical Information Agency; 2012. 

18.Kalinina A.M. Health education for patients as a factor in increasing the 

effectiveness of arterial hypertension control. Trudnyy Patsient. 2006;4(8):2-23.  

19.Kayumov U.K., Kalandarova U.A. Clinical symptoms in patients with 

prediabetes // Journal of Multidisciplinary Engineering Science and Technology 

(JMEST) 2019   No. 6. P. 10471-10473 

20.Kalandarova U.A., Kayumov U.K., Ibadova M.U. Metabolic syndrome: the 

main issues of diagnosis, prevention and treatment// Eurasian scientific journal 2015   

No. 11. P. 162-165 

21.Kershaw E.E., Flier J.S. Adipose Tissue as an Endocrine Organ. J. of 

clinic.endocrin. and metab.- 2004.- №89(6). - P. 2548-2556. 

22.Kolopkova T.A., Blinova V.V., Skvortsov Y.I., Subbotina V.G. Metabolic 

syndrome X pandemic of the XXI century. Saratovskiy Nauchno-Meditsinskiy 

Zhurnal. 2008;4(3):130-4 

23.Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and 

total cardiovascular disease mortality in middle - aged men. JAMA. 2002;288:2709-

16. 

24.Mamedov M.N. According to the materials of the I International Congress on 

prediabetes and metabolic syndrome. Arterial'naya Gipertenziya. 2005; 11 (3): 11-  

25.Mikhalevich S.I., Eshchenko A.V. Obstetric problems in patients with 

metabolic syndrome. Meditsinskie Novosti. 2011;6:19-22.  

26.Oganov R.G., Mamedov M.N., ed. School for the diagnosis and treatment of 

metabolic syndrome. Moscow: Meditsinskaya Knoga; 2007.  

27.Oganov R.G. (eds.), Eganyan R.A. School of Health. Overweight and obesity. 

Guidelines for doctors. Moscow: GEOTAR-Media, 2010. 

28.Peterson L.R., Herrero P., Schechtman K.B. et al. Effect of obesity and insulin 

resistance on myocardial substrate metabolism and efficiency in young women. 

Circulation. 2004;109:2191-6.  

29.Reaven G.M. Why a cluster is truly a cluster insulin resistance and 

cardiovascular disease. Clin.Chem. 2008;54(5):785-7. 

30.Selvin E., Coresh J., Golden S.H. et al. Glycemic control and coronary heart 

disease risk in persons with and without diabetes: the atherosclerosis risk in 

communities study. Arch Intern Med. 2005;165(16):1910-6. 

31.Yavelov I.S. Sudden cardiac death in the metabolic syndrome. Trudnyy 

Patsient. 2012;6:22-4.  

32.Yeganyan R.A., Kalinina A.M. School of Health. Overweight and obesity. 

Moscow: Geotar Media; 2010. 

33.Zhuravlev O.V., Romantsov E.B., Babtsev A.F., eds. The metabolic syndrome 

in children and adolescents: a tutorial. Blagoveshchensk: Bukvits; 2012.  

34.Zhuraeva Kh.I., Ochilova D.A., Kudratova D.Sh. Prevalence and detection of 

diabetes mellitus among the female population //Electronic scientific journal 

"Biology and Integrative Medicine". - 2016. - No. 2. - P. 80 - 87. 



Art of Medicine           Volume-1 

International Medical Scientific Journal        Issue-3 

10.5281/zenodo.5658996 

59 

35.Zhuraeva Kh.I. Kayumov L.Kh., Ubaidova D.S., Dzhabborov Zh. Zh. The 

relationship of myocardial infarction with metabolic syndrome //Electronic scientific 

journal "Biology and Integrative Medicine". - 2019. - No. 8. - P. 66 - 77. 

36.Zhuraeva Kh. I, Badridinova B.K. The relationship of arterial hypertension 

with the disturbance of glucose tolerance//Academicia: An International Multidiscip-

linary Research Journal. 2019 No. 9. - P. 17 - 22. 


